Stage IIIA Bladder Cancer AJCC v8 Clinical Trial
Official title:
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
This study evaluates the effect of bladder cancer treatment on quality of life.
PRIMARY OBJECTIVES: I. To compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the PROMIS-29 and the Bladder Cancer Index (BCI) respectively. II. To identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer. OUTLINE: This is an observational study. Patients complete surveys and also have their medical records reviewed on study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04940299 -
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
|
Phase 2 | |
Recruiting |
NCT04953104 -
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression
|
Phase 2 | |
Completed |
NCT03617913 -
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT04383743 -
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03775265 -
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
|
Phase 3 | |
Recruiting |
NCT05581589 -
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT00749892 -
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06263153 -
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
|
Phase 2 | |
Completed |
NCT03319745 -
Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
|
Phase 2 | |
Active, not recruiting |
NCT04501913 -
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
|
||
Recruiting |
NCT06040762 -
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients Receiving Chemotherapy Before Radical Cystectomy, Get Moving Trial
|
N/A | |
Recruiting |
NCT04902040 -
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
|
Phase 1/Phase 2 |